Skyline Diagnostics (Netherlands) - Nov 2007

Life Sciences Partners (LSP) and Erasmus MC Biomedical Fund have led a Series A financing round for Skyline Diagnostics BV. LSP will invest from its seed fund, which is supported by TechnoPartner, a Dutch agency of the Department of Economic Affairs.

Company

Skyline Diagnostics develops and commercialises diagnostic products for cancer using gene expression profiling. This technology allows scientists to study the activity of nearly the complete human genome in one single experiment and can provide the clinician with new insight in the development and prognosis of disease and the response to treatment. The company has three products in its development pipeline: Biochips for acute myeloid leukaemia (AML), brain tumours and myeloma (Kahler’s disease). The investment will enable the company to progress on bringing its first product, the AML Biochip, to the market. A spin off from the Erasmus University Medical Centre in Rotterdam, Skyline was founded in 2003 by the inventors of the gene expression profile for AML. The company continues to collaborate closely with several of the university’s departments, including Hematology and Bio-informatics.

People

Dr John de Koning, investment manager at LSP, has joined Skyline Diagnostics’ supervisory board. Tom Schwarz is partner at the Erasmus MC Biomedical Fund. Dr Henk Viëtor is CEO of the company, while Professor Dr B Lövenberg is the CSO.

Sourced from: Benelux unquote" 54 (Nov 2007)

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Early-stage
• Healthcare
• Netherlands